Fiche publication
Date publication
novembre 2025
Journal
Lung cancer (Amsterdam, Netherlands)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALSTEIN Véronique
,
Pr POLETTE Myriam
,
Dr NAWROCKI-RABY Béatrice
,
Dr DORMOY Valerian
Tous les auteurs :
Ancel J, Dewolf M, Nawrocki-Raby B, Durlach A, Dalstein V, Lalun N, Dormoy V, Deslée G, Gilles C, Polette M
Lien Pubmed
Résumé
Non-small cell lung cancer (NSCLC) remains a major therapeutic challenge. While PD-1/PD-L1 immunotherapies have improved outcomes, predictive biomarkers are limited. AXL, a receptor tyrosine kinase associated with poor prognosis, may impact treatment response. This study evaluates AXL expression and clinical outcomes in advanced NSCLC patients treated with immunotherapy or chemotherapy.
Mots clés
AXL, Biomarker, Immunotherapy, Non-small cell lung cancer, Resistance
Référence
Lung Cancer. 2025 11 22;210:108853
